Please select the option that best describes you:
What systemic therapy and dose adjustments would you implement for patients with pancreas cancer and cirrhosis with pancytopenia?
The patient declined palliative measures only and is motivated to receive treatment
Answer from: Medical Oncologist at Community Practice
Of the five drugs available to us, two (abraxane and irirnotecan) are a challenge in liver dysfunction with the added thrombocytopenia. The question becomes, what is the real value of a single drug versus a combination in this setting when it comes down to clinically meaningful efficacy? Capecitabin...
Sign in or Register to read more